IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m. ET to disclose topline results from their ongoing Phase 2/3 registrational trial, OptimUM-02, evaluating darovasertib in combination with crizotinib in patients with first-line HLA*A2-negative metastatic uveal melanoma. The call will include members of IDEAYA's management joined by a distinguished key opinion leader.